SC
SMMT icon

SummitTX Capital’s Summit Therapeutics SMMT Stock Holding History

SummitTX Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
+10,809
New +$192K ﹤0.01% 725
2025
Q2 		– Sell
-36,217
Closed -$699K – 989
2025
Q1 		$699K Buy
+36,217
New +$727K 0.03% 471

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SummitTX Capital's SMMT Position: Q2 2026 in Review

SummitTX Capital opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 10,809 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #725 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in SMMT as recently as Q1 2025.

SummitTX Capital first reported a position in SMMT in Q1 2025 and has held it in 2 quarters since. The position peaked at $699K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • SummitTX Capital held 10,809 shares of Summit Therapeutics worth $157K as of Q2 2026.
  • Summit Therapeutics was a new SummitTX Capital position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of SummitTX Capital's portfolio in Q2 2026, its #725 holding.
  • SummitTX Capital first reported a position in Summit Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • SummitTX Capital's Summit Therapeutics position peaked at $699K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.